🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to health experts.

A Global Health Concern

The sexually transmitted infection are escalating around the world, with estimates suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the extremely scarce treatment choices currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Results and Global Access

According to findings published in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which uses an injection and a pill. The study enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have shared positive views. Access to a single-dose, oral treatment of this kind is described as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.